Glucose-6-phosphate dehydrogenase (G6PD) deficiency

Iranian Journal of Public Health

Volumn 37, Issue 4, 2008, Pages 1-18

  Farhud, D D ^a   Yazdanpanah, L ^b  

^a Genetic Clinic   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

G6PD; Hemolytic anemia; Mediterranean variant; Oxidative damage; Sex linked inheritance

Indexed keywords

EID: 65449140276     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Mehta A, Mason PJ, Vulliamy TJ (2000). Glucose-6-phosphate dehydrogenase deficiency. Best Prac Res Clin aematol, 13: 21-38.
2. Beutler E (1994). G6PDdeficiency. Blood, 84(11): 3613-36.
3. Noori-Daloii MR, Najafi L, Ganji SM, Hajebrahimi Z, Sanati M H(2004). Molecular identification of mutations in G6PD gene in patients with favism in Iran. J Physiol Biochem, 60: 273-77.
4. Prchal JT, Gregg XT (2005). Red Cell Enzymes. Hematol, 1: 19-23.
5. Greene LS (1993). Deficiency as Protection Against falciparum Malaria: An Epidemiological Critique of Population and Exprimental Studies. Yearbook of Phys Anthropol, 36: 153-78.
6. Jain M, Brenner DA, Cui L, Lim CC, Wang B, Pimentel DR, et al. (2003). Glucose-6-Phosphate Dehydrogenase Modulator Cytosolic Redox Status and Contractile Phenotype in Adult Cardiomyocytes. Circ Res, 93: e9.
7. Shihabi A, Li WG, Miller FJ, Weintraub NL (2002). Antioxidant therapy for atherosclerotic vascular disease: the promise and the pitfalls. Am J Physiol Heart Circ Physiol, 282: H797-H802.
8. Leopold JA, Loscalzo J (2005). Oxidative Enzymopathies and Vascular Disease. Arterioscler Thromb Vasc Biol, 25:1332.
9. Tsun-Yee Chiu D, Liu TZ (1997). Free radicals and oxidative damage in human blood cells. J Biochem Sci, 4: 256-59.
10. Halliwell B (1992). Reactive Oxygen Species and the Central Nervous System. J Neurochem, 59 (5), 1609-23.
11. Savitha S, Tamilselvan J, Anusuyadevi M, Panneerselvam C (2005). Oxidative stress on mitochondrial antioxidant defense system in the aging process: role of DL-alphalipoic acid and L-carnitine. Clin Chim Acta, 355: 173-80.
12. Fico A, Paglialunga F, Cigliano L, Abrescia P, Verde P, Martini G, et al. (2004). Glucose-6-phosphate dehydrogenase plays a crucial role in protection from redoxstress-induced apoptosis. Cell Death Differ, 11: 823-831.
13. Tian WN, Braunstein LD, Apse K, Pang J, Rose M, Tian X, et al. (1999). Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J Physiol Cell Physiol, 276: 1121-31.
14. Abraham S, Soundararajan CC, Vivekanandhan S, Behari M (2005). Erythrocyte antioxidant enzymes in Parkinson, s disease. Indian J Med Res, 121: 111-15.
15. Mohanty D, Mukherjee MB, Colah RB (2004). Glucose-6-phosphate dehydrogenase deficiency in India. Symposium, 71(6): 525-29.
16. Cappellini MD, Fiorelli G (2008). Glucose-6-phosphate dehydrogenase deficiency. Lancet, 5; 64-74.
17. Kwiatkowski DP (2005). How Malaria Has Affected the Human Genome and What Human Genetics Can Teach Us about Malaria. Am J Hum Genet, 77(2): 171-92.
18. Fortin A, Stevenson MM, Gros P (2002). Susceptibility to malaria as a complex trait: big pressure from a tiny creature. Hum Mol Genet, 11: 2469-78.
19. Farhud DD, Sadighi H, Amirshahi P, Tavakkoli F Sh (1993). Serum level measurements of Gc, Cp, IgG, IgA and IgM in patients with favism in Iran. Iranian J Publ Health, 22:1-4.
20. Tripathy V, Reddy BM (2007). Present status of understanding on the G6PD deficiency and natural selection. Rev Article, 53: 193-202.
21. Anonymous (2006). Glucose-6-hosphate dehydrogenase deficiency. Genetics Home Refrence. Available from: ghr.nlm.nih.gov/condition=glucose6phosphatedehydrogenasedeficiency
22. Usanga EA, Ameen R (2000). Glucose-6-Phosphate Dehydrogenase Deficiency in Kuwait, Syria, Egypt, Iran, Jordan and Lebanon. Hum Hered, 50: 158-61.
23. Vulliamy TJ, Urso MD', Battistuzzi G, Estrada M, Foulkes N S, Martini G, et al. (1988). Diverse point mutations in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia. Proc Natl Acad Sci U S A, 85: 5171-75.
24. + molecule and provides insights into enzyme deficiency. Struc, 8(3): 293-303.
25. Anonymous.Glucose-6-phosphate dehydrogenase; G6PD. Johns Hopkins University. Available from: www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=305900.
26. Wijk RV, Huizinga EG, Prins I, Kors A, Rijksen G, Bierings M, et al. (2004). Distinct phenotypic expression of two de novo missense mutations affecting the dimer interface of glucose-6-phosphate dehydrogenase. Blood Cells Mol Dis, 32: 112-17.
27. Hundsdoerfer P, Vetter B, Kulozik AE (2002). Chronic Haemolytic Anaemia and Glucose-6-Phosphate Dehydrogenase Deficiency. Acta Haematol, 108:102-5.
28. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull WHO 1989; 67: 601-11.
29. Corons JV, Kuhl W, Pujades MA, Beutler E (1990). Molecular Genetics of the Glucose-6-Phosphate Dehydrogenase (G6PD) Mediterranean Variant and Description of a New G6PD Mutant, G6PD Andalus 1361A. Am J Hum Genet, 47:575-79.
30. Noori-Daloii MR, Soltanian S, Mohammad Gangi SH, Yousefi A, Hejazi S, Banihashem A, et al. (2006). Molecular Identification of the Most Prevalent Mutations of Glucose-6-Phosphate Dehydrogenase (G6PD) Gene in deficient Patients in Khorasan Province of Iran. J Sci I R Iran, 17(2): 103-106.
31. Warsy AS, El-Hazmi MAF (2001). G6PD deficiency, distribution and variants in Saudi Arabia. Ann Saudi Med, 21:174-77.
32. AlFadhli S, Kaaba S, Elshafey A, Salim Matra, Alawadi A, Bastaki L (2005). Molecular Characterization of Glucose-6-Phosphate Dehydrogenase Gene Defect in the Kuwaiti Population. Arch Pathol Lab Med, 129:1144-47.
33. Nafa Kh, Reghis A, Osmani N, Baghli L, Aït-Abbes H, Benabadji M, et al. (1994). At least five polymorphic mutants account for the prevalence of glucose-6-phosphate dehydrogenase deficiency in Algeria. Hum Genet, 94.
34. Vives Corrons JL, Zarza R, Aymerich JM, Boixadera J, Carrera A, Colomer D, et al. (1997). Molecular analysis of glucose-6-dehydrogenase deficiency in Spain. Sangre, 42(5):391-8.
35. Medina MD, Vaca G, Lopez-Guido B, Westwood B, Beutler E (1997). Molecular Genetics of Glucose-6-Phosphate Dehydrogenase Deficiency in Mexico. Blood Cells Mol Dis, 23: 88-94.
36. Ainoon O, Yu YH, Amir Muhriz AL, Boo NY, Cheong SK, Hamidah NH (2003). Glucose-6-phosphate dehydrogenase (G6PD) variants in Malaysian Malays. Hum Mutat, 21(1):101.
37. Nuchprayoon I, Sanpavat S, Nuchprayoon S (2002). Glucose-6-phosphate dehydrogenase (G6PD) mutations in Thailand: G6PD Viangchan (871G> A) is the most common deficiency variant in the Thai population. Hum Mutat, 19: 185- 85.
38. Noori-Daloii MR, Yousefi A, Mohammad Ganji S, Hejazi SH, Soltanian S, Sanei Moghadam E, et al. (2005). Molecular Identification of the Most Prevalent Mutation of Glucose-6-Phosphate Dehydrogenase Gene in Deficient Patients in Sistan and Balochestan Province of Iran. J Sci I R Iran, 16.
39. Karadsheh NS, Gelbart T, Schulten HJ, Efferth T, Awidi A(2005). Relationship between Molecular Variants and Clinical Manifestions in Twelve Glucose-6-Phosphate Dehydrogenase-Deficient Patients in Jordan. Acta Haematol, 114:125-26.
40. Rahimi Z, Vaisi-Raygani A, Ronald L (2006). Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Kurdish population of Western Iran. Blood Cells Mol Dis, 37: 91-4.
41. Abolghasemi H, Mehrani H, Amid A (2004). An update on the prevalence of glucose-6-phosphate dehydrogenase and neonatal jaundice in Tehran neonates. Clin Biochem, 37:241-44.
42. Mesbah-Namin SA, Sanati MH, Mowjood A, Mason PJ, Vulliamy TJ, Noori-Daloii MR (2002). Three major glucose-6-phosphate dehydrogenase-deficient polymorphic variants identified in Mazandaran state of Iran. British J Haematol, 117: 763-4.
43. th Annual Congress of the Europian Hematology Association. Hematol J, 4: 155.
44. Ohkura K, Miyashita T, Nakajama H, Matsumoto H, Matsutomo K, Rahabar S, et al. (1984). Distribution of polymorphic traits in Mazandaranian and Guilanian in Iran. Hum Hered, 34: 27-39.
45. Pishva N, Amoozgar H (2001). Hyperbilirubinemia following exchange transfusion with G6PD deficient donor blood. Ir J Med Sci, 26:143-45.
46. Khalili D, Jafroodi M, Sajedi SA, Shameli Rad M, Abdollahi F, Alipour Kanafi K, et al. (2007). Survey of the prevalence of glucose-6-phosphate dehydrogenase deficiency in Rasht-Iran. J Gilan Univ Med Sci, 63: 51-6.
47. Beutler E. Erythrocyte disorders: Anemias due to increased destruction of erythrocytes with enzyme deficiencies, Glucose-6-phosphate dehydrogenase deficiency. G6PD Deficiency Association is affiliated with Italian Federation for Rare Diseases. Available at: www.g6pd.org/favism/english/print.mv?pgid=beutler
48. Pronsky ZM, Crowe SJP (2008). Assessment: Food-Drug interactions. In: Krause's Food and Nutrition Therapy. eds, Mahan and Escott- Stump. 12th ed, Saunders Elsevier Inc. St. Louis, Missouri, P. 434.
49. Lowitt MH, Shear NH (2001). Pharmacogenomics and dermatological therapeutics. Arch Dermatol, 137.
50. WHO (2007). The Ethical, Legal and Social implications of pharmacogenomics in developing countries. Rep Int Group experts, pp. 3-13.
51. Nicol CJ, Zielenski J, Tsui LC, Wells PG (2000). An embryoprotective role for glucose-6-phosphate dehydrogenase in developemental oxidative stress and chemical tetratogenesis. Faseb J, 14: 111-27.
52. Bolchoz LJC, Morrow JD, Jollow DJ, Mc-Millan DC (2002). Primaquine-Induced Hemolytic Anemia: Effect of 6-Methoxy-8-hydroxylaminoquinoline on Rat Erythrocyte Sulfhydryl Status, Membrane Lipids, Cytoskeletal Proteins, and Morphology. Pharmacol Exp Ther, 303: 141-48.
53. Bowman ZS, Oatis JE, Whelan JL, Jollow DJ, McMillan DC (2004). Primaquine-Induced Hemolytic Anemia: Susceptibility of Normal versus Glutathione-Depleted Rat Erythrocytes to 5-Hydroxyprimaquine. J Pharmacol Exp Ther, 309: 79-85.
54. Zinkham WH, Oski FA (1996). Henna: A Potential Cause of Oxidative Hemolysis and Neonatal Hyperbilirubinemia. Pediatr, 97: 707-9.
55. McMillan DC, Sarvate SD, Oatis JE, Jollow DJ (2004). Role of Oxidant Stress in Lawsone-Induced Hemolytic Anemia. Toxicol Sci, 82: 647-55.
56. Seyedzadeh A, Hemmati M, Gheiny S (2007). Henna- Induced Severe Hemolysis:In Glucose 6- Phosphate Dehydrogenase Deficiency. Pak J Med Sci, 23: 119-21.
57. Raupp P, Hassan JA, Varughese M, Kristiansson B (2001). Henna causes life threatening haemolysis in glucose-6-phosphate dehydrogenase deficiency. Arch Dis Child, 85: 411-12.
58. Zinkham WH, Oski FA (1996). Henna: A Potential Cause of Oxidative Hemolysis and Neonatal Hyperbilirubinemia. Pediatr, 97: 707-9.
59. Ko CH, Li K, Ng PC, Fung KP, Li CL, Wong RP, et al. (2006). Pro-oxidative effects of tea and polyphenols, epigallocatechin-3-gallate and epigallocatechin, on G6PD-deficient erythrocytes in vitro. Int J Mol Med, 18:987-994.
60. th ed, Saunders Elsevier Inc. St. Louis, Missouri, P.435.
61. Anonymous. G6PD Deficiency Association is affiliated with Italian Federation for Rare Diseases. Available at: www.g6pd.org/favism/english/index.mv?pgid=intro.
62. McMillan DC, Jollow DJ (1999). Favism: divicine hemotoxicity in the rat. Toxicol Sci, 51: 310-16.
63. Hedayat SH, Farhud DD, Montazami K, Ghadiryan P (1981). The Pattern of Bean Consumption, Laboratory Findings in Patients with Favism, G-6-P-D Deficient, and a Control Group. J Trop Pediatr, 27: 110-13.
64. Farhud DD, Amirshahi P (1985). Ahaptoglobinemia in favism patients from Iran. Acta Anthropogenet, 9: 206-13.
65. Farhud DD, Amirshahi P, Hedayat SH (1979). The distribution of haptoglobin type in Bandarabas. Iranian J Publ Health, 7: 181-82.
66. Mobasheri MB, Farhud DD (2003). Investigation of ahaptoglobinemia and its association with malaria endemisity in south of Iran. Iranian J Publ Health, 32: 19-22.
67. Arese P, Bosia A, Naitana A, Gaetani S, D'Aquino M, Gaetani GF(1981). Effect of divicine and isouramil on red cell metabolism in normal and G6PD-deficient (Mediterranean variant) subjects. Possible role in the genesis of favism. Prog Clin Biol Res, 55: 725-46.
68. Pedersen JZ, Musci G, Rotilio G (1988). Electron Spin Resonance Characterization of the Radicals Produced by Enzymatic or Chemical Cleavage of Vicine. Biochem, 27: 8534-36.
69. McMillan DC, Schey KL, Meier GP, Jollow DJ (1993). Chemical Analysis and Hemolytic Activity of the Fava Bean Aglycon Divicine. Chem Res Toxicol, 6:439-44.
70. Kaplan M, Muraca M, Vreman HJ, Hammerman C, Vilei MT, Rubaltelli FF, et al. (2005). Neonatal bilirubin productionconjugation imbalance: effect of glucose-6-phosphate dehydrogenase deficiency and borderline prematurity. Arch Dis Child Fetal Neonat Ed, 90: F123-F127.
71. Dennery PA, Seidman DS, Stevenson DK (2001). Neonatal Hyperbilirubinemia. N Engl J Med, 344: 581-90.
72. Kaplan M, Hammerman C (2000). Glucose-6-Phosphate Dehydrogenase Deficiency: A Worldwide Potential Cause of Severe Neonatal Hyperbilirubinemia. Pediatr Rev Neo Rev,1: e32-e39.
73. Groenendaal F, der Grond JV, De Vries LS (2004). Cerebral Metabolism in Severe Neonatal Hyperbilirubinemia. Pediatr, 114: 291-94.
74. Kaplan M, Muraca M, Hammerman C, Vilei MT, Leiter C, Rudensky B, et al. (1998). Bilirubin Conjugation, Reflected by Conjugated Bilirubin Fractions, in Glucose-6-Phosphate Dehydrogenase-deficient Neonates: A Determining Factor in the Pathogenesis of Hyperbilirubinemia. Pediatr, 102 (3): e37.
75. Zahed Pasha A, Ahmadpoor M, Zahed Pasha Y (2006). Glucose-6-phosphate dehydrogenase Enzyme Deficiency. J Babol Univ Med Sci, 8(1).
76. Markić J, Krželj V, Markotić A, Marušić E, Stričević L, Zanchi J, et al. (2006). High Incidence of Glucose-6-phosphate Dehydrogenase Deficiency in Croatian Island Isolate: Example from Vis Island, Croatia. Croat Med J, 47: 566-70.
77. en.wikipedia.org/wiki/Glucose-6-phosphate_dehydrogenase_deficiency.
78. Frank EJ (2005). Diagnosis and Management of G6PD Deficiency. Am family phys, 72: 1277-82.
79. Wong RJ, Bhutani VK, Vreman HJ, Stevenson DK (2007). Tin Mesoporphyrin for the Prevention of Severe Neonatal Hyperbilirubinemia. Neo Rev, 8.
80. Martinez JC, Garcia HO, Otheguy LE, Drummond GS, Kappas A (1999). Control in Severe Hyperbilirubinemia in Full-term Newborns with the Inhibitor in Bilirubin Production. Pediatr, 103: 1-5.